Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pathophysiology-based therapy of epileptic encephalopathies
2016-001611-20Phase 2Terminated
- Sponsor
- University of Tübingen
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of phenytoin and lacosamide in epileptic encephalopathy (2 arms), sponsored by University of Tübingen. Primary endpoint: Seizure reduction ≥50% vs baseline. Started Sep 2016; status: terminated.
02
Drugs
phenytoinlacosamide
03
Conditions
epileptic encephalopathy
Beyond the preview
Go deeper on 2016-001611-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001611-20.